Table of Contents

company-logo

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.

Chimeric Therapeutics Dividend Announcement

• Chimeric Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Chimeric Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Chimeric Therapeutics Dividend History

Chimeric Therapeutics Dividend Yield

Chimeric Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Chimeric Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Chimeric Therapeutics Financial Ratios

P/E ratio-0.36
PEG ratio-0.02
P/B ratio2.76
ROE-230.15%
Payout ratio0.00%
Current ratio0.32
Quick ratio0.32
Cash Ratio0.30

Chimeric Therapeutics Dividend FAQ

Does Chimeric Therapeutics stock pay dividends?
Chimeric Therapeutics does not currently pay dividends to its shareholders.
Has Chimeric Therapeutics ever paid a dividend?
No, Chimeric Therapeutics has no a history of paying dividends to its shareholders. Chimeric Therapeutics is not known for its dividend payments.
Why doesn't Chimeric Therapeutics pay dividends?
There are several potential reasons why Chimeric Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Chimeric Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Chimeric Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Chimeric Therapeutics a dividend aristocrat?
Chimeric Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Chimeric Therapeutics a dividend king?
Chimeric Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Chimeric Therapeutics a dividend stock?
No, Chimeric Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Chimeric Therapeutics stocks?
To buy Chimeric Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Chimeric Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.